Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DFY58O
|
|||
| Drug Name |
RTB101
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Respiratory tract infection [ICD-11: CA45; ICD-10: J13, J15] | Phase 3 | [1] | |
| Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 2 | [2] | ||
| Company |
ResTORbio
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CREB-regulated transcription coactivator 1 (TORC1) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04139915) Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04409327) Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes. U.S. National Institutes of Health. | |||
| REF 3 | Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.